NovImmune enters exclusive antibody licensing agreement with Genentech
Plan-Les-Ouates/Switzerland– 26th July 2010 - NovImmune, an antibody-focused research and development biotech company, announced today that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.
The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development. Under the terms of the agreement NovImmune will receive an upfront payment and is eligible to receive clinical milestones and royalties on sales. Full financial terms have not been disclosed.
The EUROPEAN BIOTECHNICA AWARD 2009 goes to NovImmune
Hannover/Geneva. The winner of the 2009 EUROPEAN BIOTECHNICAAWARD is NovImmune SA from Switzerland. This biopharmaceutical company duly receivesthe lion's share of the €100,000 prize money, which is awarded each year by DeutscheMesse AG and its partners. The aim of the award is to celebrate theachievements of innovative European companies in the field of biotechnology andthe life sciences. EU Commissioner Janez PotoÄ?nik presented the prizes at today'sopening ceremony for BIOTECHNICA 2009.
NovImmune nominated for the EUROPEAN BIOTECHNICA AWARD 2009
Hannover/Geneva. 25th of August. The EUROPEAN BIOTECHNICA AWARD jury has selected the three finalists for 2009: The nominees are the biopharmaceutical companies NovImmune, Switzerland, TRION Pharma GmbH, Germany, and VIVALIS, France. The award, with prize money totalling 100,000 euros, recognizes the achievements of young, innovative European companies from the areas of biotechnology and the life sciences. It is presented annually by Deutsche Messe AG, Hannover, and its partners.
NovImmune successfully completes NI-0801 Phase I
clinical study
Plan-Les-Ouates/Geneva - 13th July 2009 - NovImmune, an
immunology-focused biotech company dedicated to the development of therapeutic
monoclonal antibodies, announced today the successful completion of the first
phase I clinical study with its fully human monoclonal antibody NI-0801 targeting
the chemokine IP-10 (CXCL10) in healthy volunteers. The randomized,
double-blinded, placebo controlled, single centre, phase I study of escalating
single intravenous doses of NI-0801 in healthy volunteers (study NI-0801-01)
demonstrated that NI-0801 is well tolerated at doses up to and including
20mg/kg.
NovImmune completes CHF
62.5 (USD 54.8) million equity financing to move portfolio forward and reacquire
product rights to lead antibodies
Plan-Les-Ouates/Geneva - 12th May 2009 - NovImmune, an immunology-focused
biotech company dedicated to the development of therapeutic monoclonal
antibodies, announced today that it has raised CHF 62.5 million (USD 54.8
million) to take back control of its lead compounds (NI-0401 and NI-0501, a
fully human monoclonal antibody to CD3 and interferon-gamma, respectively) and for
further development of its pipeline. The transaction was led by BZ Bank Aktiengesellschaft.
Panspecific antibodies: Novimmune successful in designing antibodies with multiple specifies
Plan-Les-Ouates/Geneve
- NovImmune announced today the description, for the first time, of a single
antibody engineered for double antigen binding specificity involving chemokines
as targets...
Top Roche Executive will become Chairman of NovImmune
The Geneva-based biotech company NovImmune S.A. announced today the forthcoming arrival of Eduard E. Holdener, Chief Medical Officer, and formerly Head of Global Pharmaceutical Development at F. Hoffmann-La Roche Ltd., Basel...
NovImmune raises CHF 58 million in Series B Private Financing
NovImmune SA ("NovImmune"), a Geneva-based drug development company focusing on immune mechanisms to clinically impact immune-related diseases, inflammation and organ transplantation...
NOVIMMUNE initiates Phase I/IIa trials proof-of-concept study with NI-0401, a novel fully human anti-CD3 monoclonal antibody in Crohn’s Disease
NovImmune SA (“NovImmune”) announced today that it has initiated a Phase I/IIa proof-of-concept clinical trial of its novel fully human anti-CD3 monoclonal antibody, NI-0401, a product of its own research....
Medarex Announce NovImmune Filing of Investigational New Drug Application for Fully Human Antibody for the Treatment of Autoimmune Disease
Medarex, Inc. (Nasdaq: MEDX) today announced the filing of an Investigational New Drug (IND) application in the Netherlands by its licensing partner...
Serono and Novimmune to collaborate in development of two novel treatments for autoimmune diseases
Serono (virt-x: SEO and NYSE: SRA) and NovImmune (private) have signed an exclusive agreement under which NovImmune has granted Serono...
